MedTrace Logo

Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke

NCT07279493 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-12-12

No results posted yet for this study

Summary

This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

The KPCXM18 injection

Intravenous infusion of 60 mg twice daily at intervals of 12±2 hours for 12±2 days.

DRUG

Placebo

Intravenous infusion twice a day with an interval of 12±2 hours for 12±2 days.

DRUG

The KPCXM18 injection

Intravenous infusion of 100 mg twice daily at intervals of 12±2 hours for 12±2 days.

Sponsors & Collaborators

  • Kunming Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Yongjun Wang, MD · Beijing Tiantan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-22
Primary Completion
2026-10-18
Completion
2026-10-18

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07279493 on ClinicalTrials.gov